 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12345678910111213...203204» |
- || Review, Journal: (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review. (Pubmed Central) - Jul 17, 2024
(Re-)initiation of TNF antagonists and JAK inhibitors may be relatively safe in patients with current or previous TB and the need for further treatment of underlying diseases.
- | Humira (adalimumab) / AbbVie
Journal: Multiple sclerosis associated with adalimumab use in ankylosing spondylitis. (Pubmed Central) - Jul 17, 2024
(Re-)initiation of TNF antagonists and JAK inhibitors may be relatively safe in patients with current or previous TB and the need for further treatment of underlying diseases. No abstract available
- | Remicade (infliximab) / J&J, Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie
Journal: Paediatric Uveitis - the uniqueness in clinical presentation and the efficacy of biologics treatment. (Pubmed Central) - Jul 17, 2024
Clinical presentation of the local paediatric uveitis differs from previously described features in Caucasian and other populations. According to our experience as a tertiary eye centre, Beh
- | tofacitinib / Generic mfg.
Journal: A novel approach with tofacitinib for the management of keratoderma blennorrhagicum in reactive arthritis: a case report. (Pubmed Central) - Jul 17, 2024
Subsequent use of adalimumab and secukinumab resulted in worsening skin rash, prompting a switch to tofacitinib, leading to a remarkable improvement in pustular eruptions after 20 days of treatment. This case demonstrates successful application of tofacitinib in treating severe keratoderma blennorrhagicum refractory to conventional DMARDs and biologics, offering insights into JAK inhibition for challenging rheumatic diseases with skin involvement.
- | Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Plasma Cytokines for the Prediction of the Effectiveness of TNF? Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis. (Pubmed Central) - Jul 13, 2024
The baseline levels of VEGF, sCD40L, and ICAM1, as well as IL20, could serve as potential predictors of treatment effectiveness using TNFa inhibitors. However, this hypothesis requires confirmation with a larger patient population.
- | Humira (adalimumab) / AbbVie
Journal: Efficacy of adalimumab in noninfectious pediatric uveitis: Analysis of 29 eyes from a tertiary eye care center in India. (Pubmed Central) - Jul 11, 2024
Adalimumab is effective in the treatment of pediatric noninfectious uveitis by achieving disease inactivity, reducing the recurrence rate and improving BCVA. The drug is safe and well tolerated.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. (Pubmed Central) - Jul 10, 2024
P=N/A
The drug is safe and well tolerated. Both IFX and ADA have a good safety profile and deliver a beneficial clinical and laboratory response in moderate-severe IBD patients.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Common practice patterns in the diagnosis and management of Vogt-Koyanagi-Harada syndrome: a survey study of uveitis specialists. (Pubmed Central) - Jul 10, 2024
While there are some common trends in the practice patterns for the diagnosis and treatment of patients with VKH, there was no clear consensus on the topic of IMT. There was a slight preference among uveitis specialists to use both IMT and systemic corticosteroids for the first episode of acute VKH.
- || Remicade (infliximab) / J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
Retrospective data, Review, Journal: Rescue Therapies for Steroid-Refractory Acute Severe Ulcerative Colitis: A Systemic Review and Network Meta-analysis. (Pubmed Central) - Jul 9, 2024
Tofacitinib, accelerated IFX, standard IFX, and tacrolimus significantly reduced the colectomy rates in SR ASUC patients compared with placebo. Thus, advanced therapies should be considered for rescue therapies in patients with SR ASUC.
- | Avastin (bevacizumab) / Roche, Humira (adalimumab) / AbbVie, Ilaris (canakinumab) / Novartis
Journal: Prediction of human serum concentration-time profiles of therapeutic monoclonal antibodies using common marmosets (Callithrix jacchus): Initial assessment with canakinumab, adalimumab, and bevacizumab. (Pubmed Central) - Jul 8, 2024
As a result, the observed human serum concentration-time curves of the three mAbs following intravenous administration and those of canakinumab and adalimumab following subcutaneous injections (with an assumed absorption rate constant and bioavailability) were reasonably predicted.4. Although further prediction studies using a sufficient number of other mAbs are necessary to evaluate the versatility of this model, the findings indicate that marmosets can be an alternative to preceding animals for human pharmacokinetic predictions of therapeutic mAbs.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: A case of juvenile-onset ankylosing spondylitis effectively treated with tumour necrosis factor-alpha inhibitor agents. (Pubmed Central) - Jul 8, 2024
The bath ankylosing spondylitis disease activity index (BASDAI) value was 8.0 at the time of induction and 3.1 at 6?months after the introduction of adalimumab (at a dose of 40?mg)...The BASDAI value was 2.6 at 6?months, 2.7 at 1?year, and 1.8 at 1.5?years after the introduction of infliximab, indicating that the patient had progressed well without any adverse events...TNF inhibitors were effective in treating juvenile ankylosing spondylitis in the present case without any adverse events. This case is notable because juvenile onset ankylosing spondylitis is one of the reasons for severe lumbago since childhood and because TNF inhibitors were administered promptly after diagnosis.
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Uveitis as predictor of disease flare after the first anti-TNF withdrawal in oligoarticular and polyarticular juvenile idiopathic arthritis: a multicentric Italian experience. (Pubmed Central) - Jul 8, 2024
This case is notable because juvenile onset ankylosing spondylitis is one of the reasons for severe lumbago since childhood and because TNF inhibitors were administered promptly after diagnosis. Younger age at onset, uveitis, duration of tapering, and not-persistent OligoJIA seem to be independent risk factors for earlier relapse after the first TNFi withdrawal.
- | Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
Retrospective data, Journal: A retrospective study describing the effective exchange of total blood plasma for disease control in the exacerbation of serpiginous choroiditis. (Pubmed Central) - Jul 3, 2024
The reproducible response with each recurrence suggests a strong association between the disease and autoimmunity. Furthermore, that some, as yet unknown, autoantibodies are involved in the pathogenesis of serpiginous choroiditis.
- | Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
Journal: Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Na (Pubmed Central) - Jul 3, 2024
Among patients with moderate-to-severe CD, early and delayed responders to adalimumab and ustekinumab have similar 1-year clinical outcomes. Biomarker decline can be observed through the initial 8 weeks of therapy in patients who will eventually be delayed responders, which may help differentiate from nonresponders.
- | Humira (adalimumab) / AbbVie
Retrospective data, Journal: Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. (Pubmed Central) - Jul 3, 2024
P2, P2a, P
Biomarker decline can be observed through the initial 8 weeks of therapy in patients who will eventually be delayed responders, which may help differentiate from nonresponders. In patients with RA, tofacitinib was efficacious across racial groups with similar safety outcomes; observed racial differences potentially reflect patient demographics or regional practice disparities.
- || Review, Journal: The Use of TNF-? Inhibitors in Active Ankylosing Spondylitis Treatment. (Pubmed Central) - Jul 2, 2024
Overall, TNF-? inhibitors have emerged as a cornerstone in the therapeutic algorithm against AS with a very satisfactory safety profile.
- | Humira (adalimumab) / AbbVie
Journal: Retinal Vasculitis Associated with SAPHO Syndrome Responding to Treatment with Adalimumab. (Pubmed Central) - Jul 1, 2024
We described a rare case of retinal vasculitis associated with SAPHO syndrome. Adalimumab treatment was effective in treating both osteitis and retinal vasculitis.
- | Journal: Liver enzyme profiles after initiating biological treatment in children with inflammatory bowel diseases. (Pubmed Central) - Jul 1, 2024
Benign ALT elevation is common within 3 months after starting BT (especially infliximab) and scarcely led to cessation of the treatment. AIH is a rare finding during the first year of BT.
- | Humira (adalimumab) / AbbVie
Journal: Financial impact on social security of the incorporation of adalimumab for the treatment of hidradenitis suppurativa: An (Pubmed Central) - Jun 29, 2024
AIH is a rare finding during the first year of BT. No abstract available
- | Dipentum (olsalazine sodium) / Viatris, UCB, Humira (adalimumab) / AbbVie
Journal: Refractory Crohn's Disease Responsive to Dietary Therapy: A Case Report. (Pubmed Central) - Jun 28, 2024
In conclusion, for patients whose disease is refractory to different treatments, or who develop antibodies to the medication, AIDs may offer a solution to reduce disease symptoms and progression. Education of healthcare professionals and patients alike is vital in order for Crohn's patients to gain the benefits from dietary therapy.
- | Humira (adalimumab) / AbbVie
Journal: A Case of Hepatic Tuberculosis in a Patient on Adalimumab for Ankylosing Spondylitis. (Pubmed Central) - Jun 28, 2024
Primary hepatic TB is rare, and liver involvement is often secondary to spreading from the lymphatics, portal vein, or hepatic artery. We report a case of hepatic TB in a patient on adalimumab for ankylosing spondylitis (AS).
- | Remicade (infliximab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / AbbVie
Journal: SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients - does treatment for IBD negatively affect SARS-CoV-2 antibodies? A single-centre, prospective study. (Pubmed Central) - Jun 28, 2024
Due to the immunosuppressive and biological treatment, IBD patients are exposed to a shorter persistence of SARS-CoV-2 antibodies and require booster doses. The role of gastroenterologists in educating patients about the need to continue SARS-CoV-2 vaccination remains crucial.
- | Stelara (ustekinumab) / J&J, Humira (adalimumab) / AbbVie
Journal: Single-Cell Transcriptomic and Targeted Genomic Profiling Adjusted for Inflammation and Therapy Bias Reveal CRTAM and PLCB1 as Novel Hub Genes for Anti-Tumor Necrosis Factor Alpha Therapy Response in Crohn's Disease. (Pubmed Central) - Jun 27, 2024
The motivation behind our study is to shift the paradigm of anti-TNF? biomarker discovery toward specific immune cell sub-populations using single-cell RNA sequencing and an innovative approach designed to uncover PBMCs gene expression signals, which may be masked due to the treatment or ongoing inflammation; The single-cell RNA sequencing was performed on PBMC samples from CD patients either na
- | Humira (adalimumab) / AbbVie
Journal: Chronic TNF in the aging microenvironment exacerbates Tet2-loss-of-function myeloid expansion. (Pubmed Central) - Jun 26, 2024
Examination of human rheumatoid arthritis patients with clonal hematopoiesis revealed that hematopoietic cells carrying certain mutations, including in TET2, may be sensitive to reduced TNF bioactivity following blockade with adalimumab...To our knowledge, this is the first evidence to demonstrate that TNF has a causal role in driving TET2-mutant CHIP in vivo. These findings highlight TNF as a candidate therapeutic target to control TET2-mutant CHIP.
- | Humira (adalimumab) / AbbVie
Retrospective data, Journal: Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient-reported ethnicity. (Pubmed Central) - Jun 26, 2024
These findings highlight TNF as a candidate therapeutic target to control TET2-mutant CHIP. Caucasian or Asian ethnicity does not influence response to adalimumab treatment on patients with hidradenitis suppurativa.
- | Humira (adalimumab) / AbbVie
Journal: Erythema Multiforme-Like Drug Eruption Associated With Adalimumab Treatment. (Pubmed Central) - Jun 25, 2024
Caucasian or Asian ethnicity does not influence response to adalimumab treatment on patients with hidradenitis suppurativa. No abstract available
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Clinical Patterns of Sarcoidosis Patients with and without Uveitis: Insights from a Dutch Sarcoidosis Centre. (Pubmed Central) - Jun 25, 2024
Ocular sarcoidosis was more prevalent in women. Further research is warranted to explore the implications of these findings for treatment strategies and prognostic assessments.
- | Remicade (infliximab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Alleviation of severe chronic arthritic pain using polyvalent immunoglobulins (KMP01): Two case reports. (Pubmed Central) - Jun 25, 2024
Further research is warranted to explore the implications of these findings for treatment strategies and prognostic assessments. Findings from two case reports support the rationale for using polyvalent immunoglobulins as an effective and safe alternative in arthritis patients receiving standard treatments, in particular, methotrexate and TNF-?-blocking agents.
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI, Humira (adalimumab) / AbbVie
Trial completion: Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis (clinicaltrials.gov) - Jun 25, 2024
P2, N=112, Completed, Sponsor: Assistance Publique - H
Findings from two case reports support the rationale for using polyvalent immunoglobulins as an effective and safe alternative in arthritis patients receiving standard treatments, in particular, methotrexate and TNF-?-blocking agents. Unknown status --> Completed
- | Humira (adalimumab) / AbbVie
Journal: Primary Vitreoretinal Lymphoma Masquerading as Post-Operative Endophthalmitis in a Pregnant Patient with Longstanding Idiopathic Panuveitis. (Pubmed Central) - Jun 24, 2024
The authors present a unique case of PVRL masquerading as postoperative endophthalmitis after FAi exchange in an eye with chronic panuveitis treated with adalimumab immunosuppressive therapy. The authors hypothesize that there may be a causal relationship between adalimumab and PVRL.
- | Humira (adalimumab) / AbbVie
Journal: A Robust ?-l-Fucosidase from Prevotella nigrescens for Glycoengineering Therapeutic Antibodies. (Pubmed Central) - Jun 24, 2024
This enabled the seamless incorporation of biantennary sialylglycans by Endo-S2 D184 M in a one-pot fashion to yield adalimumab in a homogeneous afucosylated glycoform with an improved binding affinity toward Fc? receptor IIIa.
- || Stelara (ustekinumab) / J&J
Retrospective data, Review, Journal: Ustekinumab in Hidradenitis Suppurativa: A Systematic Review and Meta-analysis. (Pubmed Central) - Jun 22, 2024
receptor IIIa. Ustekinumab may be a helpful treatment option to consider for HS that is recalcitrant to first-line biologic therapies, but RCTs are needed to determine optimal dosing regimens and the specific patient populations that would benefit the most from this agent.
- | Humira (adalimumab) / AbbVie
Journal: The use of adalimumab to overcome delayed wound healing after wide excision for hidradenitis suppurativa. (Pubmed Central) - Jun 22, 2024
Ustekinumab may be a helpful treatment option to consider for HS that is recalcitrant to first-line biologic therapies, but RCTs are needed to determine optimal dosing regimens and the specific patient populations that would benefit the most from this agent. No abstract available
- || Clinical, Retrospective data, Review, Journal, Monotherapy: The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis. (Pubmed Central) - Jun 21, 2024
However, there are no significant differences in safety between the different JAK inhibitors. Head-to-head trials, directly comparing one against each other, are required to provide more certain evidence.
- | Journal: Quantitative evaluation of the time-course and efficacy of targeted agents for ulcerative colitis. (Pubmed Central) - Jun 21, 2024
Infliximab and upadacitinib were determined to be the most effective biological and small targeted molecules, respectively. These findings may provide valuable implications for guiding future decision-making in clinical practice and drug development for UC.
- | Humira (adalimumab) / AbbVie
Journal: Delayed Diagnosis of SMARCA4-Deficient Undifferentiated Tumor in a Heavy Smoker Male Patient: Discovered Through Bone Sampling, with Extensive Distant Metastases and Concurrent Granulomatous Disease, Leading to Patient Fatality. (Pubmed Central) - Jun 20, 2024
A 69-year-old heavy-smoker man with adalimumab-treated rheumatoid arthritis presented with multiple lesions...These tumors present diverse clinical manifestations, affecting multiple organ systems. This report underscores the diagnostic complexities associated with complex clinical presentation and highlights the importance of multidisciplinary collaboration in addressing challenging clinical scenarios, particularly among heavy smoker male patients and intricate radiological presentations.
- | Kineret (anakinra) / SOBI, Humira (adalimumab) / AbbVie
Journal: IL-1 and TNF mediates IL-6 signaling at the maternal-fetal interface during intrauterine inflammation. (Pubmed Central) - Jun 19, 2024
Both IL1 and TNF blockade suppressed LPS-induced IL6 mRNAs in the AMC and variably decreased elements of IL6 trans-signaling. These data suggest that IL1 and TNF blockers may be useful anti-inflammatory agents via suppression of IL6 signaling at the maternal-fetal interface.
- | Humira (adalimumab) / AbbVie
Journal: Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab. (Pubmed Central) - Jun 19, 2024
These data suggest that IL1 and TNF blockers may be useful anti-inflammatory agents via suppression of IL6 signaling at the maternal-fetal interface. No abstract available
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Observational data, Journal: Dynamics of serum levels of TNF-? in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-? biological drugs. (Pubmed Central) - Jun 18, 2024
biological drugs. Key Points
- | Humira (adalimumab) / AbbVie
Journal: The Dilemma of Balancing Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-?) Biologics for Psoriatic Arthritis Control With the Risk of Severe Systemic Infection. (Pubmed Central) - Jun 17, 2024
This case underscores the need for further research into prophylactic treatment and monitoring protocols to manage recurrent infections during anti-TNF-? therapy effectively.
- ||| Humira (adalimumab) / AbbVie
Journal, Adverse events, Real-world evidence, Real-world: Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: a real-world cohort study from 7580 patients. (Pubmed Central) - Jun 17, 2024
Tofacitinib use in patients with RA may increase the risk of dyslipidaemia to some extent compared to adalimumab. However, there is no differences on MACE and all-cause mortality.
- || Humira (adalimumab) / AbbVie, Actemra SC (tocilizumab SC) / Roche, Halozyme
Review, Journal: NeuroBehcet's-related intracranial hypertension without cerebral venous thrombosis: case report and review of literature. (Pubmed Central) - Jun 15, 2024
We demonstrated how novel use of Tocilizumab may have a role in the management of NBrIHwCVT. Based on our literature review, patients were more likely to be young, female, display a non-inflammatory CSF picture, be treated with steroids and harbour a possibility of recurrence.
- Humira (adalimumab) / AbbVie
Observational data, Retrospective data, Journal: Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immune-mediated inflammatory diseases-an observational study. (Pubmed Central) - Jun 13, 2024
The 12-month persistence rates (95% CI) were 81% (76%, 90%) and 61% (56%, 67%), respectively. Overall, this study suggests that optimal adalimumab persistence can be achieved with either a structured PSP or healthcare support from other sources, but this was not the case more than a decade ago.
- | Humira (adalimumab) / AbbVie
Journal: Comparison of Target- and IgG-Enrichment Strategies to Measure Adalimumab Concentrations in Human Plasma Using an Immunocapture-Liquid Chromatography-High-Resolution Mass Spectrometry Platform. (Pubmed Central) - Jun 12, 2024
Overall, this study suggests that optimal adalimumab persistence can be achieved with either a structured PSP or healthcare support from other sources, but this was not the case more than a decade ago. No abstract available
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Subretinal Fibrosis Developing 10 Years After First Presentation with Chronic Ocular Sarcoidosis in a Child. (Pubmed Central) - Jun 12, 2024
Ultimately, the patient's intraocular inflammation was successfully controlled by using intravitreal steroids (Triamcinolone and Fluocinolone acetonide implant)...The index case progressed to sight-robbing bilateral subretinal fibrosis, a rare complication of ocular sarcoidosis despite a combination of conventional and biologic anti-inflammatory therapies. There is a pressing need to develop new treatment agents for refractory non-infectious uveitis.
- | Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: ADALIMUMAB VERSUS INFLIXIMAB IN LUMINAL PEDIATRIC CROHN'S DISEASE: COMPARABLE OUTCOMES IN A PROSPECTIVE MULTICENTER COHORT STUDY. (Pubmed Central) - Jun 10, 2024
Children with CD achieved favorable outcomes at 1 year with either ADA or IFX as first anti-TNF agents. Those receiving IFX did not have significantly superior outcomes compared with clinically similar children receiving ADA.
- | Bimzelx (bimekizumab) / UCB, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Journal: S2k guideline for the treatment of hidradenitis suppurativa / acne inversa - Short version. (Pubmed Central) - Jun 10, 2024
Various surgical procedures are available for the predominantly non-inflammatory disease form. Drug/surgical combinations are considered a holistic therapy method.
- | Humira (adalimumab) / AbbVie
Journal: Presumed Fungal Retinitis Following Adalimumab Therapy for Juvenile Idiopathic Arthritis: A Rare Case Report. (Pubmed Central) - Jun 10, 2024
A vitreous biopsy was performed, and intravitreal voriconazole was administered, but microbiological tests were negative...By the 6-week follow-up, her retinitis had fully resolved, maintaining excellent visual acuity. This case underscores the need for a high index of suspicion for infection in patients with long-term immunosuppression, highlighting the importance of early therapeutic intervention.
- | Rinvoq (upadacitinib) / AbbVie
Journal: Efficacy and Safety of Upadacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction for Intractable Ulcerative Colitis. (Pubmed Central) - Jun 10, 2024
Combination comprising UPA plus intensive GMA appears likely to achieve satisfactory induction of clinical remission and histopathological improvement for patients with intractable UC for whom conventional agents and anti-tumor necrosis factor-? antibody have failed.
- | Humira (adalimumab) / AbbVie
Journal, Head-to-Head: A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial. (Pubmed Central) - Jun 8, 2024
P4
The final prediction model seems promising to select patients who could successfully increase their ADA dose interval. The model should be validated externally before it may be applied in clinical practice.